BRPI0516576C8 - Vetores quiméricos - Google Patents

Vetores quiméricos

Info

Publication number
BRPI0516576C8
BRPI0516576C8 BRPI0516576A BRPI0516576C8 BR PI0516576 C8 BRPI0516576 C8 BR PI0516576C8 BR PI0516576 A BRPI0516576 A BR PI0516576A BR PI0516576 C8 BRPI0516576 C8 BR PI0516576C8
Authority
BR
Brazil
Prior art keywords
vectors
chimerical
relates
chimeric
chimeric vectors
Prior art date
Application number
Other languages
English (en)
Inventor
Francis Audonnet Jean-Christophe
Jiansheng Yao
May Loosmore Sheena
Original Assignee
Boehringer Ingelheim Animal Health Usa Inc
Merial Ltd
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health Usa Inc, Merial Ltd, Merial Inc filed Critical Boehringer Ingelheim Animal Health Usa Inc
Publication of BRPI0516576A publication Critical patent/BRPI0516576A/pt
Publication of BRPI0516576B1 publication Critical patent/BRPI0516576B1/pt
Publication of BRPI0516576B8 publication Critical patent/BRPI0516576B8/pt
Publication of BRPI0516576C8 publication Critical patent/BRPI0516576C8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

vetores quiméricos. a presente invenção refere-se a vetores quiméricos. mais especificamente, a invenção refere-se a vetores de poxvírus e vírus recombinantes que são capazes de expressar um replicon de rna alfaviral que expressa uma seqüência heteróloga de interesse.
BRPI0516576-8 2004-10-05 2005-10-04 Vetores quiméricos BRPI0516576C8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/958,267 US7998733B2 (en) 2004-10-05 2004-10-05 Chimeric vectors
US10/958,267 2004-10-05
PCT/US2005/035785 WO2006041897A2 (en) 2004-10-05 2005-10-04 Chimeric vectors

Publications (4)

Publication Number Publication Date
BRPI0516576A BRPI0516576A (pt) 2008-09-16
BRPI0516576B1 BRPI0516576B1 (pt) 2019-09-24
BRPI0516576B8 BRPI0516576B8 (pt) 2021-05-25
BRPI0516576C8 true BRPI0516576C8 (pt) 2022-06-14

Family

ID=36126051

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516576-8 BRPI0516576C8 (pt) 2004-10-05 2005-10-04 Vetores quiméricos

Country Status (6)

Country Link
US (1) US7998733B2 (pt)
EP (1) EP1809337B1 (pt)
BR (1) BRPI0516576C8 (pt)
CA (1) CA2583147C (pt)
MX (1) MX2007004168A (pt)
WO (1) WO2006041897A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065476A1 (en) * 2007-11-30 2009-06-03 Institut Pasteur A mammalian cell-based screening assay to identify inhibitors of alphaviruses
PT2734230T (pt) * 2011-07-20 2019-02-27 Roussy Inst Gustave Vacina recombinante contra o vírus da leucemia felina contendo um gene de envelope do vírus da leucemia felina otimizado
NZ759538A (en) * 2013-11-28 2022-10-28 Bavarian Nordic As Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
CA3009928A1 (en) 2016-01-29 2017-08-03 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
EP4085130A4 (en) * 2019-12-31 2024-04-10 Elixirgen Therapeutics Inc TEMPERATURE-BASED TRANSIENT DELIVERY OF NUCLEIC ACIDS AND PROTEINS TO CELLS AND TISSUES
MX2022007910A (es) * 2019-12-31 2022-08-25 Elixirgen Therapeutics Inc Distribucion transitoria basada en temperatura de ácidos nucleicos y proteínas de zscan4 a células y tejidos.
CN112143754B (zh) * 2020-09-30 2021-05-18 扬州大学 猪盖塔病毒感染性克隆及其建构方法及应用
US20230158138A1 (en) * 2021-11-23 2023-05-25 Wisconsin Alumni Research Foundation Modified gene vaccines against avian coronaviruses and methods of using the same
US11873507B2 (en) * 2021-11-29 2024-01-16 Replicate Bioscience, Inc. Compositions and methods for expression of IL-12 and IL-1RA
GB2624391A (en) * 2022-11-15 2024-05-22 Univ Cape Town Recombinant LSDV vectored bovine coronavirus antigen constructs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
WO1994017813A1 (en) 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
BR0113577A (pt) * 2000-08-29 2004-07-06 Wyeth Corp Empacotamento de partìculas de replicon de vìrus de rna de filamento positivo
DE60233061D1 (de) * 2001-09-06 2009-09-03 Alphavax Inc Alphavirus replikon-vektorsysteme
US20040110295A1 (en) * 2002-05-28 2004-06-10 Maxygen, Inc., A Delaware Corporation Nucleic acid vectors
ES2222095B1 (es) * 2003-07-02 2005-11-16 Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria Inia Virus adn recombinantes que comprenden un adn complementario de un replicon de un virus arn y sus aplicaciones.

Also Published As

Publication number Publication date
BRPI0516576B1 (pt) 2019-09-24
CA2583147C (en) 2013-06-25
EP1809337A2 (en) 2007-07-25
US7998733B2 (en) 2011-08-16
WO2006041897A3 (en) 2006-12-21
EP1809337A4 (en) 2008-02-13
CA2583147A1 (en) 2006-04-20
BRPI0516576B8 (pt) 2021-05-25
EP1809337B1 (en) 2017-08-23
BRPI0516576A (pt) 2008-09-16
US20060073594A1 (en) 2006-04-06
MX2007004168A (es) 2007-09-11
WO2006041897A2 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
BRPI0516576C8 (pt) Vetores quiméricos
AU2018256548A1 (en) Activation of bioluminescence by structural complementation
MX363533B (es) Proteínas de fusión que comprenden partes de unión a pdgf y vegf y métodos de uso de las mismas.
SG177025A1 (en) Hepatitis b virus specific antibody and uses thereof
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
CY1118567T1 (el) Αναστολεις του ιου της ηπατιτιδας c
EA201690403A1 (ru) Композиции и способы для модулирования рнк
CY1114509T1 (el) Αναστολεις της ns5a toy hcv
BR112018001683A2 (pt) adenovírus recombinante, composição, uso de um adenovírus ou uma composição, e, adenovírus de símio não humano.
MX2019010341A (es) Uso combinado de trampas gdf y activadores del receptor de eritropoyetina para incrementar los niveles de globulos rojos.
ATE544774T1 (de) Rnai-modulation von mll-af4 und verwendungen dafür
EA201491361A1 (ru) Ингибиторы вируса гепатита c
WO2006078645A3 (en) Heterologous polypeptide expression using low multiplicity of infection of viruses
WO2006133911A3 (en) Hepatitis c virus nucleic acid vaccine
MY173638A (en) Parainfluenza virus 5 based vaccines
ZA201603187B (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
MX2019007252A (es) Metodos y composiciones para vacunas del virus del dengue.
EP3956439A4 (en) RECOMBINANT CLASSICAL SWINE FEVER VIRUS
MX2009003300A (es) Vectores de rhinovirus recombinantes.
WO2013033319A3 (en) A cluster of neutralizing antibodies to hepatitis c virus
EP2600894A4 (en) MODIFIED HEPATITIS C VIRUS PROTEINS
TN2016000140A1 (en) Recombinant glycoproteins and uses thereof.
MX2021009154A (es) Selectividad eficaz de proteinas recombinantes.
WO2008005487A3 (en) Peptide sequences for modulation of protein kinase c
BR112017024786A2 (pt) virus oncolíticos recombinantes e usos dos mesmos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: MERIAL, INC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/10/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22E Other requirements [chapter 22.5 patent gazette]

Free format text: FORMULADA EXIGENCIA PARA ADEQUACAO OU CUMPRIMENTO DE DISPOSICOES LEGAIS NO PRAZO DE 60 (SESSENTA) DIAS DESTA DATA.

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2542, DE 24/09/2019. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 24/09/2019, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.

B25A Requested transfer of rights approved

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)